An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials
10.4062/biomolther.2024.228
- Author:
Mi Kyung KIM
1
;
Hye Soon KIM
Author Information
1. Department of Internal Medicine, Keimyung University, School of Medicine, Dongsan Hospital, Daegu 42601, Republic of Korea
- Publication Type:Invited Review
- From:Biomolecules & Therapeutics
2025;33(1):5-17
- CountryRepublic of Korea
- Language:English
-
Abstract:
Obesity requires treatment as it is associated with health problems such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular diseases, and some cancers, which increase mortality rates. Achieving sufficient weight loss to reduce obesity-related diseases requires a variety of interventions, including comprehensive lifestyle modification of diet and exercise, change in behavior, anti-obesity medications, and surgery. To date, anti-obesity agents with various mechanisms of action have been developed, and mostly reduce energy intake, resulting in weight loss of about 5% to 10% compared to baseline. Recently developed drugs and those currently under development have been shown to reduce body weight by more than 10% and are expected to reduce obesity-related complications. This article summarizes existing and emerging anti-obesity medications, with a particular focus on those evaluated in clinical trials.
